PATH Malaria Vaccine Initiative


Published on

PATH Malaria Vaccine Initiative's (MVI) presentation at the 2009 Partnering for Cures meeting in New York. MVI's mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

PATH Malaria Vaccine Initiative

  1. 1. PATH Malaria Vaccine Initiative Christian Loucq, MD Director, PATH Malaria Vaccine Initiative 2 December 2009
  2. 2. MVI mission, vision, and goal <ul><li>Mission: To accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world </li></ul><ul><li>Vision: A world free from malaria </li></ul><ul><li>Goal: To develop by 2025 a malaria vaccine with 80% or greater efficacy that lasts for at least four years </li></ul>MVI was established in 1999 as a program of PATH, an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health.
  3. 3. Malaria 101 <ul><li>A parasitic infection transmitted through the bite of infected female Anopheles mosquitoes </li></ul><ul><li>Plasmodium falciparum and P . vivax cause the vast majority of clinical cases </li></ul><ul><li>An estimated 250 million cases of malaria occur every year; roughly 3.3 billion people are at risk of contracting the disease. </li></ul><ul><li>Of 900,000 deaths worldwide each year, 91% occur in Africa—most of them among infants and children under 5 years of age. </li></ul>
  4. 4. How MVI works <ul><li>MVI partners to achieve its mission; success depends on the strength of its collaborations. </li></ul><ul><li>MVI is a non-profit vaccine investor ; it supports others to do the development. </li></ul><ul><li>Partners include academia, government agencies, biotechs, and pharmaceutical companies. </li></ul><ul><li>MVI identifies potentially promising malaria vaccine approaches for development. </li></ul><ul><li>MVI systematically moves projects through the development process. </li></ul>
  5. 5. Challenges to developing malaria vaccines <ul><li>Commercial </li></ul><ul><ul><li>Limited market in developed countries </li></ul></ul><ul><ul><li>Malaria-endemic countries are mostly poor </li></ul></ul><ul><ul><li>Vaccine development is high-risk, high-cost </li></ul></ul><ul><li>Scientific </li></ul><ul><ul><li>No vaccine is in human use against a parasite </li></ul></ul><ul><ul><li>Malaria parasite has ~6,000 genes, many more than a virus </li></ul></ul><ul><ul><li>How to predict a vaccine candidate’s success? </li></ul></ul>
  6. 6. Malaria vaccines: The missing tool <ul><li>Tools such as drugs, bed nets and insecticides have reduced the burden of malaria in some areas, however </li></ul><ul><ul><li>The parasite develops resistance to drugs </li></ul></ul><ul><ul><li>The mosquito develops resistance to insecticides </li></ul></ul><ul><li>From smallpox to polio to whooping cough, vaccines have offered a cost-effective and efficacious means of preventing disease and death. </li></ul><ul><li>Malaria vaccines would represent powerful, complementary tools to existing interventions. </li></ul>
  7. 7. MVI’s R&D strategy <ul><li>Pre-erythrocytic vaccine approaches that target P. falciparum </li></ul><ul><li>Approaches that target P. vivax </li></ul><ul><li>Transmission-blocking vaccine approaches that target P. falciparum and P. vivax </li></ul><ul><li>Feasibility studies to ensure availability of vaccine approaches aligned with strategy </li></ul><ul><li>Evaluation technologies across all program areas </li></ul>
  8. 8. Strengths of MVI’s PDP model <ul><li>Strong and diverse collaborations to implement coherent R&D strategy </li></ul><ul><li>Product development and testing </li></ul><ul><li>Develops products to fit within the existing system </li></ul><ul><li>Combines public health imperative with private sector rigor </li></ul>
  9. 9. Our partners and collaborators…
  10. 10. Our portfolio
  11. 11. Key accomplishments <ul><li>The first large-scale Phase 3 trial of a malaria vaccine candidate, called RTS,S, is underway in 7 African countries. </li></ul><ul><li>More than 30 African countries have endorsed a framework that will pave the way for informed decision-making to use, or not, a malaria vaccine. </li></ul><ul><li>Progress in developing and refining evaluation technologies that allow malaria vaccine researchers to assess vaccine approaches in vitro. </li></ul><ul><li>The first-in-human trial of a vaccine approach modeled after the experiments of 40 years ago is currently underway. </li></ul>
  12. 12. MVI revenue and expenditures
  13. 13. R&D partner funding (2009–2013) (in USD millions)
  14. 14. Funding gaps <ul><li>RTS,S </li></ul><ul><ul><li>Malaria transmission intensity (data for policymakers) </li></ul></ul><ul><ul><li>Phase 3 immunology (data for implementation, future R&D) </li></ul></ul><ul><ul><li>Phase 4 studies (post-licensure studies) </li></ul></ul><ul><li>Attenuated sporozoites </li></ul><ul><li>Prime-boost </li></ul><ul><li>Transmission-blocking </li></ul><ul><li>Human challenge trial facilities </li></ul><ul><ul><li>Critical to maintain facilities in “slow” periods </li></ul></ul>
  15. 15. MVI management and advisors <ul><li>MVI Leadership Team: </li></ul><ul><li>Ashley Birkett </li></ul><ul><li>Carla Botting </li></ul><ul><li>Alan Brooks </li></ul><ul><li>Sally Ethelston </li></ul><ul><li>Santiago Ferro </li></ul><ul><li>Christian Loucq </li></ul><ul><li>Katya Spielberg </li></ul><ul><li>Scientific Advisors include: </li></ul><ul><li>John H. Adams </li></ul><ul><li>John Boslego </li></ul><ul><li>Brendan Crabb </li></ul><ul><li>David Kaslow </li></ul><ul><li>Tom Monath </li></ul><ul><li>Moriya Tsuji </li></ul><ul><li>Marie Paul Kieny </li></ul><ul><li>David Salisbury </li></ul><ul><li>George Siber </li></ul>
  16. 16. Portfolio management at MVI Director Christian Loucq Leadership Team (Unit Heads) Technical Advisory Groups Vaccine Science Portfolio Advisory Council Unit Staff Members (Functional Competencies) R&D Portfolio Management Committee Business Development Teams Vaccine Strategic Program Teams Business Development Teams Business Development Teams Vaccine Strategic Program Teams Vaccine Strategic Program Teams Vaccine Program Areas Technical Advisory Groups Technical Advisory Groups <ul><ul><li>Portfolio Management System </li></ul></ul><ul><ul><li>Advisory bodies </li></ul></ul>
  17. 17. Summary <ul><li>MVI’s goal of an ≥80% effective malaria vaccine is achievable. </li></ul><ul><li>Vaccine development is costly, but the benefits are huge. </li></ul><ul><li>Individual and smaller institutional funders can make a difference. </li></ul>“… With a vaccine candidate now in a late stage Phase III trial across Africa, we are closer than ever before to having a new tool that could strengthen the arsenal at our disposal….”
  18. 18. Thank you to … <ul><li>The dozens of non-profit organizations, government agencies, companies, and scientists who collaborate with us </li></ul><ul><li>The Bill & Melinda Gates Foundation, US Agency for International Development (USAID), ExxonMobil Foundation, and individual donors </li></ul>